Company
Aadi
Realizing the potential of mTOR inhibition using precision medicine and albumin-bound nanoparticle technology
Also known as Aadi Bioscience, Aadi Bioscience, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Aadi Bioscience, Inc.
- aadibio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s leading asset, FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension), targets cancers driven by mTOR pathway activation, including advanced malignant PEComa, a rare type of sarcoma.
Funding snapshot
- Total raised
- $452MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $100M2025-03-04
Funding rounds
- Round, 2025
- $100M2025-03-04, SEC form D sold, 17 investors
- Round, 2022
- $72.5M2022-09-26, SEC form D sold, 13 investors
- Round, 2021
- $82.5M2021-08-26, SEC form D sold, 15 investors
- Round, 2021
- $155M2021-08-26, SEC form D sold, 31 investors
- Round, 2017
- $41.8M2017-03-15, SEC form D sold, 264 investors
About the company
- Status notes
- Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company developing precision therapies for genetically-defined cancers.
Products
- Other
- FYARRO
Loading relationship preview